What investment strategy does dievini Hopp BioTech holding focus on?

dievini Hopp BioTech holding focuses on VC, Growth strategies in the private equity space.

How many portfolio companies does dievini Hopp BioTech holding have?

dievini Hopp BioTech holding has 4 active portfolio companies and 2 completed exits and 1 fund tracked on GP Intel.

Where is dievini Hopp BioTech holding headquartered?

dievini Hopp BioTech holding is headquartered in Walldorf, Germany.

What is dievini Hopp BioTech holding's assets under management?

dievini Hopp BioTech holding manages approximately €1.4B in assets under management.

When was dievini Hopp BioTech holding founded?

dievini Hopp BioTech holding was founded in 2005.

What sectors does dievini Hopp BioTech holding invest in?

dievini Hopp BioTech holding invests across Healthcare.

What are dievini Hopp BioTech holding's recent exits?

Recent realized exits by dievini Hopp BioTech holding include: CureVac (2025) to BioNTech.

Home/GPs/dievini Hopp BioTech holding

DetailCard

dievini Hopp BioTech holding

Walldorf, Germany·Founded 2005·

Venture Capital Growth Equity

·dievini.de

dievini Hopp BioTech holding is the evergreen life-sciences family-office holding of SAP co-founder Dietmar Hopp and his family, based in Walldorf, Germany. Formalized in 2005 and led today by managing director Dr. Mathias Hothum (with founders Friedrich von Bohlen und Halbach and Christof Hettich), it invests patient balance-sheet capital directly into biotech, therapeutics and diagnostics companies focused on oncology, neurology, infectiology, cell therapy and pharmaceutical formulations, primarily in Germany and Europe. Notable holdings include CureVac, Immatics, AC Immune, Apogenix, Heidelberg Pharma and Molecular Health, with more than EUR 1.3 billion deployed across its portfolio.

AUM

€1.4B

Funds

vintages 2005

Portfolio

Exits

dievini Hopp BioTech holding is a Walldorf venture capital firm with €1.4B AUM, 4 active companies and 2 exits.

SectorsHealthcare

Sector breakdown

6 companies

Biotech

4 · 67%

SaaS

1 · 17%

Pharma

1 · 17%

Key facts

HQWalldorf, Germany

Founded2005

Websitedievini.de

Recent exits

dievini Hopp BioTech holding exited Molecular Health in 2026 after 22 years.

dievini Hopp BioTech holding sold CureVac to BioNTech in 2025 after 20 years.

Coverage notes

1 fund tracked, 6 portfolio companies (4 active · 2 realized). Verified weekly from public filings and deal announcements.

Funds & portfolio

Every fund dievini Hopp BioTech holding has raised, with its portfolio companies. Hand-checked from public filings.

1 fund

Fund

Strategy

Vintage

Size

Assets

Exits

dievini Hopp BioTech holding (Evergreen Balance Sheet)Active

Evergreen2005€1.4B4 assets2 exits

Evergreen

2005 · 21yr

€1.4B

Unrealized

4 held

Company	Entry
Apogenix Biotech · Germany	2005
Heidelberg Pharma Biotech · Germany	2009
Immatics Biotech · Germany	2006
Novaliq Pharma · Germany	2007

Realized

2 exits

Company	Entry	Exit	Type	Buyer	MOIC
CureVac Biotech · Germany	2005	2025	Trade Sale	BioNTech	–
Molecular Health SaaS · Germany	2004	2026	–	–	–

Frequently asked questions

What investment strategy does dievini Hopp BioTech holding focus on?: dievini Hopp BioTech holding focuses on VC, Growth strategies in the private equity space.
How many portfolio companies does dievini Hopp BioTech holding have?: dievini Hopp BioTech holding has 4 active portfolio companies and 2 completed exits and 1 fund tracked on GP Intel.
Where is dievini Hopp BioTech holding headquartered?: dievini Hopp BioTech holding is headquartered in Walldorf, Germany.
What is dievini Hopp BioTech holding's assets under management?: dievini Hopp BioTech holding manages approximately €1.4B in assets under management.
When was dievini Hopp BioTech holding founded?: dievini Hopp BioTech holding was founded in 2005.
What sectors does dievini Hopp BioTech holding invest in?: dievini Hopp BioTech holding invests across Healthcare.
What are dievini Hopp BioTech holding's recent exits?: Recent realized exits by dievini Hopp BioTech holding include: CureVac (2025) to BioNTech.